# Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/impact-of-baseline-glp-1-receptor-agonist-use-on-albuminuria-reduction-and/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Rajiv Agarwal,Jennifer B. Green,Hiddo J.L. Heerspink,Johannes F.E. Mann,Janet B. McGill,Amy K. Mottl,Masaomi Nangaku,Julio Rosenstock,Muthiah Vaduganathan,Meike Brinker,Charlie Scott,Li Li,Na Li,Katja Rohwedder,Peter Rossing |
| Citations | 12 |
| DOI | 10.2337/dc25-1673 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://research.rug.nl/en/publications/483000be-a778-4e2f-ad8b-9600781b7f10 |
| OpenAlex ID | https://openalex.org/W4414340936 |
| PMID | 40968755 |
| Type | article |
| Year | 2025 |

## Paper authors

- [Masaomi Nangaku](https://scholariq.org/researchers/masaomi-nangaku/)
- [Hiddo J.L. Heerspink](https://scholariq.org/researchers/hiddo-j-l-heerspink/)
- [Julio Rosenstock](https://scholariq.org/researchers/julio-rosenstock/)
- [Muthiah Vaduganathan](https://scholariq.org/researchers/muthiah-vaduganathan/)
- [Peter Rossing](https://scholariq.org/researchers/peter-rossing/)

## Paper funders

- [Pharmaceuticals Bayer](https://scholariq.org/funders/pharmaceuticals-bayer/)

## Paper journal

- [Diabetes Care](https://scholariq.org/journals/diabetes-care/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.